Sunshine Biopharma, a pharmaceutical company offering and researching life-saving medicines in a variety of therapeutic areas including oncology and antivirals  announced that its wholly owned Canadian subsidiary, Nora Pharma Inc., has launched two new generic prescription drugs. 

The newly launched drugs are Olanzapine and Olanzapine ODT. Olanzapine is a generic version of Zyprexa. Olanzapine is indicated for the acute and maintenance treatment of schizophrenia and related psychotic disorders. Olanzapine is also indicated for the acute treatment of manic or mixed episodes of bipolar I disorder. 

Nora Pharma's Olanzapine is available in bottles of 100 tablets for the Canadian market in strengths of 2.5mg, 5mg, 7.5mg, 10mg, 15mg and 20mg. Nora Pharma's Olanzapine ODT (Orally Disintegrating Tablets) is available for the Canadian market in strengths of 5mg, 10mg, 15mg and 20mg in blisters of 30 tablets. 

In addition to its use as a monotherapy, Olanzapine is used in combination with Lithium or Valproate for treatment of depressive episodes of bipolar I disorder and in combination with Fluoxetine for treatment-resistant depression. 

"We continue to strengthen our presence in the Canadian generic drugs market, currently estimated to be at $9.4 billion and projected to grow to $19.2 billion by 2032," said Dr. Steve Slilaty, CEO of Sunshine Biopharma. "We eagerly anticipate launching more products in 2025," he added.